Guided Therapeutics, Inc.
GTHP
$0.20
-$0.03-12.28%
OTC PK
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | 58,900.00% | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | 58,900.00% | -- | -- | -- |
| Cost of Revenue | -- | 4,300.00% | -- | -- | -- |
| Gross Profit | -- | 23,000.00% | -- | -- | -- |
| SG&A Expenses | 39.41% | 234.54% | -14.67% | 63.74% | 10.03% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -27.05% | 193.53% | -2.85% | 34.35% | 13.42% |
| Operating Income | 27.05% | -83.60% | 13.55% | -16.49% | -15.32% |
| Income Before Tax | -17.10% | -86.81% | -13.46% | -14.39% | -6.22% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -17.10% | -86.81% | -13.46% | -14.39% | -6.22% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -17.10% | -86.81% | -13.46% | -14.39% | -6.22% |
| EBIT | 27.05% | -83.60% | 13.55% | -16.49% | -15.32% |
| EBITDA | 27.18% | -83.72% | 13.60% | -16.56% | -15.41% |
| EPS Basic | -67.65% | -28.95% | 20.66% | 19.26% | 16.05% |
| Normalized Basic EPS | 7.89% | -33.82% | 31.51% | 19.75% | 20.83% |
| EPS Diluted | -14.00% | 23.83% | 17.36% | 19.26% | 0.00% |
| Normalized Diluted EPS | 7.89% | -33.82% | 31.51% | 19.75% | 20.83% |
| Average Basic Shares Outstanding | 30.08% | 37.40% | 43.22% | 40.82% | 24.73% |
| Average Diluted Shares Outstanding | 30.08% | 37.40% | 43.22% | 40.82% | 24.73% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |